Evidence map›Paper›PMID 35140970›Full record

ArticleClinical case reports2022

Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.

Makiko Suga, Kentaro Fukushima, Tomoaki Ueda, Yasuyuki Arai, Shunsaku Nakagawa, Yosuke Minami, Jun Toda, Akihisa Hino, Jiro Fujita, Takafumi Yokota and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Makiko SugaDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Kentaro FukushimaDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.ORCID https://orcid.org/0000-0002-8003-2584
Tomoaki UedaDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Yasuyuki AraiDepartment of Hematology and Oncology Kyoto University Hospital Kyoto Japan.
Shunsaku NakagawaDepartment of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan.
Yosuke MinamiDepartment of Hematology National Cancer Center Hospital East Kashiwa Japan.
Jun TodaDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Akihisa HinoDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Jiro FujitaDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Takafumi YokotaDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
Naoki HosenDepartment of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.
The University of Osaka · JPKyoto University Hospital · JPNational Cancer Center Hospital East · JPOsaka International University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FMS-like tyrosine kinase 3-internal tandem duplication (

Indexed as

acute myeloid leukemiaCNS involvementFLT3inhibitorstem cell transplantation

Identifiers

PMID35140970
PMCPMC8815089
OpenAlexW4210639116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.